Hutch News
Results per Page:
Test of a new 'germline-targeting' HIV vaccine prepares to launch
Vaccine’s unique protein designed to start process of building powerful antibodies against AIDS virus
HIV antibody trial results offer 'proof of concept'
Outcome of AMP shows feasibility of developing potent antibody combinations to block HIV
Community engagement in HIV trials guides equity for COVID-19 vaccine studies
New study highlights longstanding barriers to diversity in prior decade of vaccine trials, despite federal guidelines
Biostatisticians draft blueprints for COVID-19 vax trials
Hutch group applies skills honed during decades of HIV prevention trials to bring about safe and effective vaccines for a new pandemic
Building trust in safe and effective COVID-19 vaccines
Convincing millions to get vaccinated will take more than data, facts and figures
Tailoring vaccine trial recruitment to individual communities
From the HVTN, Vaccine and Infectious Disease Division
CoVPN team leads campaign to ensure diversity in COVID-19 vaccine trials
Fred Hutch-based experts' extensive media efforts drive conversations and awareness about the importance of inclusive participation
After 20 years, Wakefield retires from HIV Vaccine Trials Network
'He created the DNA of our organization'
Experts share insights on coronavirus vaccines at Fred Hutch virtual event
Dr. Tom Lynch interviews former Hutch President Dr. Larry Corey and NIAID vaccine chief Dr. John Mascola
Q&A: Dr. Larry Corey at the center of COVID-19 vaccine research
Fred Hutch scientists will play key roles in 'harmonizing' clinical trials
Injectable HIV drug prevents infections
Early data shows fewer infections than with daily pill; trial halted
Improving HIV clinical trials with mobile technology
From the HIV Vaccine Trials Network, Vaccine and Infectious Disease Division
Machine learning predicts HIV pseudovirus antibody neutralization
From the Gilbert group, Vaccine and Infectious Disease Division
Scientists strategize to stop HIV infections, work toward cure
A hot topic for a big scientific conference convening in Seattle
The interplay between antibodies and T cells in HIV risk
From the HVTN and Vaccine and Infectious Disease Division
Two is better than one
McElrath Laboratory, Vaccine and Infectious Disease Division
Training tomorrow's HIV researchers
With no end yet to the pandemic, a program supports young South African physician-scientists
Predicting a durable immune response
From HIV Vaccine Trails Network and Vaccine and Infectious Disease Division